Andrew J Murphy Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Andrew J Murphy is EVP Research of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 49,074 shares of REGN, which is worth approximately $34.4 Million. The most recent transaction as insider was on Dec 16, 2024, when has been sold 1,054 shares (Common Stock) at a price of $730.81 per share, resulting in proceeds of $770,273. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 49.1K

1.59% 3M change

1.59% 12M change

Total Value Held $34.4 Million

ANDREW J MURPHY Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 16 2024	SELL Payment of exercise price or tax liability	$770,273 $730.81 p/Share	1,054 Reduced 2.1%	49,074 Common Stock
Dec 09 2024	SELL Payment of exercise price or tax liability	$387,204 $787.0 p/Share	492 Reduced 0.97%	50,128 Common Stock
Dec 06 2024	BUY Grant, award, or other acquisition	-	3,499 Added 6.47%	50,620 Common Stock
Nov 08 2024	SELL Bona fide gift	-	1,185 Reduced 2.45%	47,121 Common Stock
Aug 14 2024	SELL Open market or private sale	$7,321,840 $1150.69 p/Share	6,363 Reduced 11.64%	48,306 Common Stock
Aug 13 2024	SELL Payment of exercise price or tax liability	$15,566,499 $1141.49 p/Share	13,637 Reduced 19.96%	54,669 Common Stock
Aug 13 2024	BUY Exercise of conversion of derivative security	$7,993,200 $399.66 p/Share	20,000 Added 22.65%	68,306 Common Stock
Mar 14 2024	SELL Open market or private sale	$5,545,203 $958.88 p/Share	5,783 Reduced 10.69%	48,306 Common Stock
Mar 13 2024	SELL Payment of exercise price or tax liability	$13,816,364 $971.82 p/Share	14,217 Reduced 20.81%	54,089 Common Stock
Mar 13 2024	BUY Exercise of conversion of derivative security	$7,993,200 $399.66 p/Share	20,000 Added 22.65%	68,306 Common Stock
Dec 12 2023	SELL Payment of exercise price or tax liability	$6,559,828 $856.71 p/Share	7,657 Reduced 13.68%	48,306 Common Stock
Dec 11 2023	SELL Payment of exercise price or tax liability	$4,873,775 $844.09 p/Share	5,774 Reduced 9.35%	55,963 Common Stock
Dec 08 2023	SELL Payment of exercise price or tax liability	$745,066 $843.79 p/Share	883 Reduced 1.49%	58,538 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	3,199 Added 4.93%	61,737 Common Stock
Dec 05 2023	SELL Open market or private sale	$5,333,376 $816.0 p/Share	6,536 Reduced 9.91%	59,421 Common Stock
Dec 04 2023	SELL Payment of exercise price or tax liability	$10,954,041 $813.58 p/Share	13,464 Reduced 16.95%	65,957 Common Stock
Dec 04 2023	BUY Exercise of conversion of derivative security	$5,408,600 $270.43 p/Share	20,000 Added 20.12%	79,421 Common Stock
Nov 14 2023	SELL Open market or private sale	$5,195,872 $800.35 p/Share	6,492 Reduced 9.85%	59,421 Common Stock
Nov 13 2023	SELL Payment of exercise price or tax liability	$10,748,180 $795.69 p/Share	13,508 Reduced 17.01%	65,913 Common Stock
Nov 13 2023	BUY Exercise of conversion of derivative security	$5,408,600 $270.43 p/Share	20,000 Added 20.12%	79,421 Common Stock
May 09 2023	SELL Bona fide gift	-	1,326 Reduced 2.18%	59,421 Common Stock
Dec 16 2022	BUY Grant, award, or other acquisition	-	4,129 Added 6.36%	60,747 Common Stock
Dec 09 2022	SELL Payment of exercise price or tax liability	$370,613 $753.28 p/Share	492 Reduced 0.86%	56,618 Common Stock
Nov 15 2022	SELL Open market or private sale	$2,718,166 $730.69 p/Share	3,720 Reduced 6.12%	57,110 Common Stock
Nov 14 2022	SELL Bona fide gift	-	1,360 Reduced 2.33%	57,110 Common Stock

AJM

Andrew J Murphy

EVP Research

Tarrytown, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account